MMSI vs. HAE, ICUI, IRTC, AXNX, PRCT, IART, TNDM, NARI, ATEC, and GMED
Should you be buying Merit Medical Systems stock or one of its competitors? The main competitors of Merit Medical Systems include Haemonetics (HAE), ICU Medical (ICUI), iRhythm Technologies (IRTC), Axonics (AXNX), PROCEPT BioRobotics (PRCT), Integra LifeSciences (IART), Tandem Diabetes Care (TNDM), Inari Medical (NARI), Alphatec (ATEC), and Globus Medical (GMED). These companies are all part of the "surgical & medical instruments" industry.
Haemonetics (NYSE:HAE) and Merit Medical Systems (NASDAQ:MMSI) are both mid-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their community ranking, profitability, media sentiment, analyst recommendations, institutional ownership, risk, earnings, valuation and dividends.
Haemonetics has higher earnings, but lower revenue than Merit Medical Systems. Haemonetics is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.
Haemonetics presently has a consensus target price of $104.67, indicating a potential upside of 13.19%. Merit Medical Systems has a consensus target price of $92.78, indicating a potential upside of 21.07%. Given Haemonetics' stronger consensus rating and higher probable upside, analysts clearly believe Merit Medical Systems is more favorable than Haemonetics.
Haemonetics has a beta of 0.34, meaning that its stock price is 66% less volatile than the S&P 500. Comparatively, Merit Medical Systems has a beta of 0.91, meaning that its stock price is 9% less volatile than the S&P 500.
Merit Medical Systems received 31 more outperform votes than Haemonetics when rated by MarketBeat users. Likewise, 68.90% of users gave Merit Medical Systems an outperform vote while only 60.86% of users gave Haemonetics an outperform vote.
99.7% of Haemonetics shares are owned by institutional investors. Comparatively, 99.7% of Merit Medical Systems shares are owned by institutional investors. 1.8% of Haemonetics shares are owned by insiders. Comparatively, 3.7% of Merit Medical Systems shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
In the previous week, Merit Medical Systems had 14 more articles in the media than Haemonetics. MarketBeat recorded 22 mentions for Merit Medical Systems and 8 mentions for Haemonetics. Haemonetics' average media sentiment score of 0.75 beat Merit Medical Systems' score of 0.42 indicating that Merit Medical Systems is being referred to more favorably in the news media.
Haemonetics has a net margin of 9.97% compared to Haemonetics' net margin of 7.94%. Merit Medical Systems' return on equity of 22.37% beat Haemonetics' return on equity.
Summary
Merit Medical Systems beats Haemonetics on 11 of the 18 factors compared between the two stocks.
Get Merit Medical Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for MMSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MMSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Merit Medical Systems Competitors List
Related Companies and Tools
